SA
Create Free Alerts
Forte Biosciences, Inc.FBRXNASDAQ
Loading
OverviewIntelligenceChartsNews

Latest News

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
businesswire.com

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Boa.

Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
businesswire.com

Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Boa.

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
businesswire.com

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings. Forte's CEO, Paul Wagner, PhD will be presenting at the Guggenheim Emerging Outlook: Biotech Summit at 8:30 am ET on February 11th hosted at the Lotte New York Palace in New York, NY. Additionally, on March 4th at 1:50 pm ET, Dr. Wagner will.

Investors Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX)
defenseworld.net

Investors Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX)

Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock investors bought 30,205 call options on the company. This is an increase of approximately 1,663% compared to the typical daily volume of 1,713 call options. Forte Biosciences Stock Down 6.8% NASDAQ FBRX opened at $32.04

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
businesswire.com

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's B.

Federated Hermes Inc. Buys New Shares in Forte Biosciences, Inc. $FBRX
defenseworld.net

Federated Hermes Inc. Buys New Shares in Forte Biosciences, Inc. $FBRX

Federated Hermes Inc. purchased a new position in shares of Forte Biosciences, Inc. (NASDAQ: FBRX) in the second quarter, according to its most recent filing with the SEC. The firm purchased 1,072,233 shares of the company's stock, valued at approximately $13,864,000. Federated Hermes Inc. owned 16.30% of Forte Biosciences at the end of

Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)
defenseworld.net

Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX)

Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock traders purchased 30,205 call options on the company. This represents an increase of 1,663% compared to the average daily volume of 1,713 call options. Forte Biosciences Trading Down 4.6% FBRX stock opened at $19.08 on Thursday.

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
businesswire.com

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's B.

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
businesswire.com

Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its third quarter 2025 financial results and provided a business update. “We continue to make excellent progress with FB102,” said Forte Biosciences CEO Paul Wagner, PhD. “The US IND is now open and enrolment in the FB102 phase 2 celiac disease (CeD) clinical trial has expanded to US sites with top.

Forte Biosciences, Inc. $FBRX Stake Boosted by AlphaQuest LLC
defenseworld.net

Forte Biosciences, Inc. $FBRX Stake Boosted by AlphaQuest LLC

AlphaQuest LLC grew its stake in shares of Forte Biosciences, Inc. (NASDAQ: FBRX) by 300.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,897 shares of the company's stock after buying an additional 12,680 shares during the quarter. AlphaQuest LLC owned

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
businesswire.com

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards in the form of options to purchase a total of 125,000 shares of comm.

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
businesswire.com

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation “FB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study - Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital” at the Tampere Celiac Disease Symposium 2025 (Tampere, Finland).

Forte Biosciences, Inc. Announces Results and Provides Update
businesswire.com

Forte Biosciences, Inc. Announces Results and Provides Update

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its second quarter 2025 financial results and provided a business update. “I am deeply appreciative of the Forte team's incredible accomplishments in initiating 3 clinical trials for FB102 with data readouts shortly.” said Forte Biosciences CEO Paul Wagner, PhD. “We have begun dosing subjects in th.

Forte Biosciences Announces Pricing of $75 Million Public Offering
businesswire.com

Forte Biosciences Announces Pricing of $75 Million Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up to 619,606 shares of common stock at a price to the public of $11.999 per pre-funded warrant, which rep.

Forte Biosciences Announces Proposed Public Offering
businesswire.com

Forte Biosciences Announces Proposed Public Offering

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares.

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study
businesswire.com

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive data from a Phase 1b trial in celiac disease for lead program FB102 (FB102-101). The company will be hosting a conference call today at 8:30 am ET. Prof. Jason Tye-Din, Head of Celiac Research at the Walter and Eliza Hall Institute and principal investigator in the FB102-101 study will be.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance